These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 975818)

  • 1. Contraceptive efficacy of once-weekly oral administration of 2.5 mg R 2323.
    Sakiz E; Azadian-Boulanger G; Ojasoo T; Laraque F
    Contraception; 1976 Sep; 14(3):275-84. PubMed ID: 975818
    [No Abstract]   [Full Text] [Related]  

  • 2. Lack of clinical contraceptive efficacy of large doses of r 2323 given before implantation or after a missed period.
    Mora G; Faúndes A; Johansson ED
    Contraception; 1975 Aug; 12(2):211-20. PubMed ID: 1139957
    [No Abstract]   [Full Text] [Related]  

  • 3. Contraceptive effectiveness of Silastic implants containing the progestin R-2323.
    Coutinho EM; Da Silva AR; Carreira CM; Chaves MC; Adeodato Filho J
    Contraception; 1975 Jun; 11(6):625-35. PubMed ID: 1137935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial with subdermal implants containing norgestrienone.
    Diaz S; Pavez M; Quinteros E; Diaz J; Robertson DN; Croxatto HB
    Contraception; 1978 Oct; 18(4):429-40. PubMed ID: 720075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of weekly administration of an oral progestogen -R 2323- on the ovarian function.
    Victor A; Johansson ED
    Contraception; 1975 Jul; 12(1):89-94. PubMed ID: 1139951
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eighteen months contraception following subdermal insertion of silastic capsules containing norgestrienone.
    Da Silva AR; Coutinho EM
    Int J Fertil; 1978; 23(3):185-92. PubMed ID: 40892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraceptive steroid administration by subdermal implants: serum concentrations of R-2323, estrogen and progesterone in rhesus monkeys.
    Bahgat MR; Atkinson LE
    Contraception; 1977 Mar; 15(3):335-45. PubMed ID: 880812
    [No Abstract]   [Full Text] [Related]  

  • 9. Antithrombin III and oral contraception with progestagen-only preparation.
    Conard J; Samama M; Horellou MN; Zorn JR; Neau C
    Lancet; 1979 Sep; 2(8140):471. PubMed ID: 89530
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hormonal anovulation with a single monthly oral dose].
    Palomo A; Caballero A; Jáñez J; Sainz-Pardo F
    Tokoginecol Pract; 1976 May; 35(384):547-64. PubMed ID: 1014005
    [No Abstract]   [Full Text] [Related]  

  • 11. Release of contraceptive steroids from sustained release dosage forms and resulting plasma levels.
    Nash HA; Robertson DN; Jackanicz TM
    Contraception; 1978 Oct; 18(4):395-409. PubMed ID: 720073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of midcycle contraceptive (R 2323) on the human endometrium.
    Azadian-Boulanger G; Secchi J; Laraque F; Raynaud JP; Sakiz E
    Am J Obstet Gynecol; 1976 Aug; 125(8):1049-56. PubMed ID: 782250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroid release from silastic capsules and rods.
    Nash HA; Robertson DN; Moo Young AJ; Atkinson LE
    Contraception; 1978 Oct; 18(4):367-94. PubMed ID: 720072
    [No Abstract]   [Full Text] [Related]  

  • 14. The plasma concentration of a synthetic progestin, R 2323, released from polysilastic vaginal rings.
    Viinikka L; Victor A; Jänne O; Raynaud JP
    Contraception; 1975 Sep; 12(3):309-16. PubMed ID: 1164849
    [No Abstract]   [Full Text] [Related]  

  • 15. [Preliminary trials of an oral chemical contraceptive for men].
    Salat-Baroux J; Le Lorier G; Sakiz E; Rotman J; Piquet JM
    J Gynecol Obstet Biol Reprod (Paris); 1976 Sep; 5(6):831-42. PubMed ID: 1026762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience in india with a once-a-month oral contraceptive pill: qingestanol and quinestrol.
    Tejuja S; Choudhury AD; Saxena NC; Malhotra U; Bhinder G
    Contraception; 1974 Oct; 10(4):375-83. PubMed ID: 4448057
    [No Abstract]   [Full Text] [Related]  

  • 17. Contraception with long acting subdermal implants: II. Measured and perceived effects in international clinical trials.
    Coutinho E; da Silva AR; Mattos CE; Nielsen NC; Osler M; Wiese J
    Contraception; 1978 Oct; 18(4):335-53. PubMed ID: 363346
    [No Abstract]   [Full Text] [Related]  

  • 18. Norplant: reversible implant contraception.
    Sivin I; Robertson DN; Stern J; Croxatto HB; Diaz S; Coutinho E; da Silva AR; Alvarez Sanchez F; Faundes A; McDonald O; Holma P; Nielsen NC; Osler M; Nash HA
    Stud Fam Plann; 1980; 11(7-8):227-35. PubMed ID: 6996230
    [No Abstract]   [Full Text] [Related]  

  • 19. Contraception with long acting subdermal implants: I. An effective and acceptable modality in international clinical trials.
    Coutinho E; da Silva AR; Mattos CE; Nielsen NC; Osler M; Wiese J
    Contraception; 1978 Oct; 18(4):315-33. PubMed ID: 363345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of a once-a-week steroid contraceptive (R2323) on lipid and carbohydrate metabolism in women during three months of use.
    Spellacy WN; Buhi WC; Dumbaugh VA; Birk SA
    Fertil Steril; 1978 Sep; 30(3):289-92. PubMed ID: 710600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.